Related Experiment Video
Updated: Apr 25, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Sensor-augmented pump and multiple daily injection therapy in the United States and Canada: post-hoc analysis of a
Bruce A Perkins1, Elise M Halpern1, Andrej Orszag1
1Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Objective:
Effectiveness of advanced technologies for diabetes management may differ depending on national healthcare models or population characteristics. In the setting of a cross-national trial, we aimed to compare efficacy of sensor-augmented pump (SAP) therapy in the United States (US) and Canada.
Methods:
In the clinical trial Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3), 329 adults with type 1 diabetes were randomly allocated to either SAP or glargine-based multiple daily injection (MDI) therapy at 26 US sites (n=271) and 4 Canadian sites (n=58). A bootstrap analysis was performed to confirm significant differences in baseline characteristics. For the primary analysis, we compared the baseline to 1-year change in glycated hemoglobin (A1C) between Canadian and US subjects.
Results:
At baseline, compared with US subjects, Canadian subjects were more likely to be students (19% vs. 7%, p<0.01) and to consume alcohol (91% vs. 63%, p<0.01). Although Canadian subjects had greater A1C reductions from baseline compared with US subjects (p=0.02), the incremental benefit of SAP was similar in the US (SAP compared with MDI, -0.93%±0.73% vs. -0.31%±0.81%, p<0.001) and Canada (-1.14%±0.72% vs. -0.67%±0.71%, p<0.001). Mean sensor use was significantly higher in Canada than in the US (79% vs. 68% of the time, p<0.001).
Conclusions:
Despite differences in baseline characteristics and sensor adherence, SAP efficacy was similar between US and Canadian participants. As long as the intervention is administered with a similar level of expertise as was conducted in the trial, it is likely to be applicable in diverse clinical practice settings.
More Related Videos
Related Concept Videos
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Modified-Release Drug Delivery Systems: Rate-Programmed II

